semaglutide new england journal of medicine Cardiac Trials | ~~ Most popular trial post #2023 ~~ GLP1 agonism in overweight/obese patients to reduce cardiovascular mortality? This landmark trial clinicaltrials #medicalresearch | NEJM Group

That statement surprises most people, but it is the foundational truth that shapes everything else in this guide

In total, 37 studies published through February 2025 were included, covering 9,341 participants

Liraglutide and semaglutide are available in the UK and the U.S

Metabolic: Euglycemic DKA The risk of euglycemic DKA is very uncommon, but its a clinically important and real complication to be aware of in patients using GLP-1 agonists

GLP-1 RAs = glucagon-like peptide-1 receptor agonists GLP-1/GIPRAs = dual glucagon-like peptide-1 / glucose-dependent insulinotrophic peptide receptor co-agonists ANZCAs latest clinical practice recommendations were updated and released in April 2025 here are the key changes you need to know

It transforms retatrutide from a powerful appetite suppressant into a metabolic reshaping tool